DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Abstract Biomarker-enriched, chemotherapy-free treatments for patients with advanced gastric and gastroesophageal junction cancer have not been widely explored. In this multicenter, phase 2 trial (NCT04363801), we evaluated the efficacy and safety of second-line doublet immunotherapy, combining DKN-...

Full description

Saved in:
Bibliographic Details
Main Authors: Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A. Tejani, Beodeul Kang, Michael H. Kagey, Melissa Stilian, Calvin Jia, Cynthia A. Sirard, Jaffer A. Ajani, Samuel J. Klempner
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61420-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-61420-x

Similar Items